European Journal of Obstetrics & Gynecology and Reproductive Biology
Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival
Introduction
The close two-way clinical relationship between cancer and venous thromboembolism (VTE) has been known since Trousseau's time [1]. Vascular endothelial damage, stasis of blood flow and hypercoagulability are the three arms of Virchow's triad and cancer is known to affect all three. Ovarian cancer has been shown to have a high incidence of VTE compared to other cancers [2], with clear cell carcinoma carrying the highest incidence of 11–27% [3], [4], [5]. The cause of this increased risk of VTE is multifactorial, with reduced physical activity, chemotherapy, extensive cytoreductive surgery and release of procoagulant factors from cancer cells contributing to the risk [6]. The diagnosis of VTE is often the first symptom of occult malignant disease and has been shown to significantly affect overall survival in patients with ovarian cancer [7], [8].
Factors contributing to the risk of VTE in cancer can be divided into patient-, cancer- and/or treatment-related. Advanced age [9], comorbidities [10], history of prior VTE and prolonged immobility [11] increase the risks of VTE. Cancer induces a hypercoagulable state [12], the severity of which is related to the type, stage, grade and location of the cancer [4], [13]. Chemotherapy [14], [15], surgery [16] and the newer anti-angiogenesis agents [17] used in the treatment of ovarian cancer are associated with an increased risk of venous thrombosis.
In line with these findings, recent guidelines advise extended low molecular weight heparin (LMWH) prophylaxis following surgery for gynecological cancers beyond the patient's hospital stay [18]. LMWH is not without risk, however, and thrombocytopenia and heparin-induced thrombosis (HIT) are examples of complications of heparin treatment. Identification of risk factors for VTE will aid in selection of patients for extended prophylaxis.
We investigated the incidence of VTE in a population of ovarian cancer patients treated in our center between 2006 and 2010 prior to adoption of extended prophylaxis. Our objective was to determine the predisposing factors for VTE in our population and to determine the influence of VTE on overall survival in ovarian cancer patients.
Section snippets
Patient population
Data from all patients diagnosed and treated for ovarian cancer from January 2006 to December 2010 in St James's Hospital Gynaecology Oncology Unit were extracted from the gynaecology oncology database. The database records all patient demographic features, type of cancer (histology, stage, grade), treatment received (type of surgery, chemotherapy), laboratory results and significant events arising during the follow-up period. General practice/community records were checked to confirm accuracy.
Patient demographics
Three hundred and fifty patients were identified from the database. Six patients were excluded, one because clinical details were incomplete and five who were on long term anticoagulant therapy, and 344 patients were included in the final analysis. Follow up data were available for 12 and 60 months following the diagnosis of ovarian cancer.
The median (IQR) age of the patients was 57 (48–67) years: 21% of patients had a BMI equal to or more than 30 kg/m2. The histology types were borderline (n =
Comments
Gynecological malignancies and ovarian cancer in particular are associated with high rates of VTE. The treatment and prevention of VTE are challenging in these patients after major surgery, as pelvic surgery itself is an additional risk factor for VTE. Although the introduction of LMWH prophylaxis has reduced the incidence of VTE in ovarian cancer patients, some patients develop VTE despite anticoagulation and there is uncertainty as to the requirement for protracted prophylaxis for all or some
Conflict of interest
None of the authors has a conflict of interest.
References (37)
- et al.
Venous thromboembolism in ovarian cancer
Gynecol Oncol
(2007) - et al.
When ‘never-events’ occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes
Gynecol Oncol
(2010) - et al.
Thromboembolic complications in patients with clear cell carcinoma of the ovary
Gynecol Oncol
(2007) - et al.
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism
J Thromb Haemost
(2004) - et al.
Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer
Gynecol Oncol
(2007) - et al.
The incidence of venous thromboembolism among patients with primary lung cancer
J Thromb Haemost
(2008) - et al.
Chemotherapy-induced thrombosis
Thromb Res
(2006) - et al.
Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Chest
(2012) - et al.
Ovarian cancer and venous thromboembolic risk
Gynecol Oncol
(2005) - et al.
Deep venous thrombosis in gynecological oncology: incidence and clinical symptoms study
Eur J Obstet Gynecol Reprod Biol
(2009)
Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression
Obstet Gynecol
The relationship between body mass index, activated protein C resistance and risk of venous thrombosis
J Thromb Haemost
Phlegmasia alba dolens
Clin Med l’Hotel-Dieu Paris
Clear-cell cancer of the ovary—is it chemosensitive
Int J Gynecol Cancer
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells
Br J Cancer
Risk factors associated with venous thromboembolic events in patients with malignancy
Blood Coagul Fibrinolysis
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project
Ann Surg
The hypercoagulable state of malignancy: pathogenesis and current debate
Neoplasia
Cited by (91)
Does the diagnostic timing of cancer-associated thromboembolism influence the survival outcome in ovarian cancer patients?
2024, Journal of the Formosan Medical AssociationRight middle cerebral artery stroke secondary to ovarian clear cell carcinoma in a 35-year-old: A case report
2023, Case Reports in Women's HealthTime to rethink extended thromboprophylaxis after cancer surgery?
2023, Journal of Thrombosis and Haemostasis